227results about "Immunoglobulins against protease inhibitors" patented technology

The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.

The present invention provides anti-PCI antibodies having Protein C inhibitor (PCI)-neutralizing activity, and the uses thereof. Through the generation and screening of anti-PCI antibodies, the inventors successfully isolated anti-PCI antibodies which inhibit PCI's inhibitory effect on the production and activity of activated Protein C (aPC). The antibodies of the present invention suppress PCI's inhibitory effect on aPC production and / or the aPC inactivation by PCI, and thus can be used to maintain aPC activity and sustain the effects of aPC physiological activities, such as suppression of the activation of blood coagulation system and anti-inflammatory functions. The present invention also provides uses of the antibodies of the present invention in treating diseases such as thrombosis and sepsis using aPC. In treatments by aPC administration, the therapeutic effect of aPC can be sustained by administering an antibody of the present invention. The antibodies of the present invention can be used in the treatment and prevention of diseases such as thrombosis and sepsis.

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

Factors for extending the ability of isolated pluripotent stem cells to generate extraembryonic lineages in vivo, following in vitro culture, herein, chemical extenders of pluripotency (CEP). Methodsof extending the ability of a pluripotent cell to generate embryonic and extraembryonic lineages. The cell to be reprogrammed is contacted with effective amounts of the CEPs for a sufficient period oftime to reprogram the cell into a chemically induced extended pluripotent cell (ciEPSC). ciEPSC are identified as an extended pluripotent cell based on properties including: (i) morphologically and (ii) functionally for example, based on their ability contribute to both TE and ICM, in vivo. The ciEPSCs can be cultured or induced to differentiate into cells of a desired type, and used in a numberof applications, including but not limited to cell therapy and tissue engineering.

The invention relates to stable and low viscous (<50 cP) protein containing compositions, in particular, but not exclusively stable antibody containing compositions and to the use of said stable proteins in therapy, in particular for the subcutaneous delivery of said stable protein.

The present invention relates to a new means for the treatment of focal ischemic cerebral infarction (ischemic stroke). It has been found that reduction of α2-antiplasmin leads to a significantly smaller focal cerebral infarct size. The invention therefore provides the use of compounds that reduce α2-antiplasmin concentration or activity in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).

The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministrating an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.

The invention relates to the field of protein engineering, in particular to a method for preparing CysC-paired monoclonal antibodies, which comprises the following steps of: screening hybridoma cells having specific binding with CysC after fusing mouse splenic cells and myeloma cells capable of generating CysC antibodies, preparing cells for generating the monoclonal antibodies, finishing first-time cell fusion, further purifying out the monoclonal antibodies, and selecting one monoclonal antibody to be marked with horse radish peroxidase; then implementing the second-time fusion of the mouse splenic cells and the myeloma cells; finishing CysC-antigen coating on an elisa plate, adding a hybridoma-cell cultural supernatant obtained through the second-time cell fusion to elisa-plate holes, arranging a blank control hole, subsequently adding the monoclonal antibody marked with the horse radish peroxidase to the elisa-plate holes, incubating at the temperature of 37 DEG C for 30 minutes, adding a substrate to each hole for color rendering, and measuring a light absorption value under 450nm after stopping reaction through sulfuric acid; and selecting the uninhibited holes as the paired monoclonal antibodies.

The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and / or α-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

The invention provides a method of inhibiting viral infection of a mammalian cell, said method comprising reducing or inhibiting ps20 polypeptide expressed by said cell. Suitably ps20 is inhibited by contacting said cell with an antibody capable of binding to ps20 polypeptide. Suitably said antibody is ps20 neutralising antibody. The invention also provides antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding ps20 polypeptide, or antisense ps20 polynucleotide for use as a medicament for viral infection. The invention also provides a method of identifying an agent for inhibiting a viral infection, comprising determining level of ps20 expression in first and second samples, the first contacted with test agent; and comparing the level of ps20 expression in said first and second samples; wherein lower level of ps20 expression in said first sample relative to said second sample identifies test agent as an agent for inhibiting a viral infection.

The invention relates to stable and low viscous (<50 cP) protein containing compositions, in particular, but not exclusively stable antibody containing compositions and to the use of said stable proteins in therapy, in particular for the subcutaneous delivery of said stable protein.

The invention discloses a recombined human cystatin-C protein with natural activity and a preparation method thereof. According to the preparation method, lots of stable recombined human cystatin-C proteins are expressed and purified by employing a gene engineering technique, and the recombined human cystatin-C proteins are cut by utilizing the protease, so that the recombined human cystatin-C protein has high natural activity. The recombined human cystatin-C protein can be used for immune preparation of monoclonal antibodies and multi-antibody blood serum, and excellent raw materials are provided for preparing stable cystatin-C detection agents and quality control products thereof.

The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass spectrometry.

The present invention relates to methods for inhibiting malignant tumour growth, invasion and / or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be brought about by administering compounds interacting with the IPNME, but also administration of compounds interacting with transcription of genes encoding the IPNME is a possibility. The invention also relates to methods of selecting and identifying compounds in the therapeutical methods, as well of the use of such compounds in the treatment of malignancies.

[Problem] To provide an anti-human PAI-1 antibody for prevention and treatment of pulmonary fibrosis by binding to active human PAI-1 and inhibiting effects mediated by active human PAI-1. [Solution] The inventors studied anti-PAI-1 antibodies, and provided an anti-human PAI-1 antibody that contains: a heavy-chain variable region comprising the amino acid sequence from amino acid 1 to 118 in SEQ ID No. 2; and a light-chain variable region comprising the amino acid sequence from amino acid 1 to 108 in SEQ ID No. 4.

In accordance with the present invention, there are provided fully human monoclonal antibodies against secretory leukocyte protease inhibitor (SLPI) and antigen binding fragments thereof. Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules are provided. The invention provides antibodies and antigen-binding fragments thereof specifically bind to SLPI; act to neutralize SLPI activity; and can modulate SLPI effects.

Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.

A method for analyzing secretome, a biomarker for lung cancer metastasis, and a siRNA compound for inhibiting lung cancer metastasis are disclosed. The method for analyzing secretome of the present invention comprises the following steps: (A) collecting proteome secreted from a cell; (B) providing a purification gel, wherein the purification gel comprises a low-density layer, and a high-density layer, and the low-density layer is stacked on the high-density layer; (C) adding the proteome on the low-density layer, and separating the proteome through the low-density layer and the high-density layer of the purification gel; (D) collecting the separated proteome on the interface between the low-density layer and high-density layer, and tagging the separated proteome with a reagent after digestion; and (E) analyzing the separated proteome tagged with the reagent, and comparing an analysis result with a proteomic database.

The invention provides reagents and methods for diagnosing kidney disease in a human or animal.

The invention discloses preparation and application of an adjacent hybridization dual-mode immunosensor based on MXene nanosheet photo-thermal amplification. Polyethyleneimine (PEI) modified TiO2 disc-shaped nanoparticles are used as a substrate, and a large amount of capture substrate deoxyribonucleic acids are fixed on a sensing interface through electrodeposition of gold. Two deoxyribonucleic acid probes are both labeled with a human epididymis protein 4 (HE4) antibody of a target object, and after the deoxyribonucleic acid probes as a recognition part of HE4 are captured by DNA3, the HE4 induces adjacent hybridization between primary antibody-labeled DNA1 and secondary antibody-labeled DNA2 by immunorecognition. An MXene nanosheet is loaded with a large amount of thionine, so that theMXene nanosheet can be effectively intercalated into a double-stranded DNA groove formed by hybridization, can be used as a signal probe for electrochemical-temperature dual modes, and realizes amplification of electrochemical signals due to temperature rise generated by the photo-thermal effect. Under the irradiation of an 808 nm infrared laser device, high-sensitivity detection of the HE4 is realized.

Derivatives and conjugates of indinavir for generation of antibodies and labeled conjugates for use for detection of indinavir in biological samples. The derivatives are synthesized out of the indane ring hydroxyl group or the pyridine ring nitrogen of indinavir. Also disclosed is synthesis of a major metabolite of indinavir (M6) in a single step from indinavir using palladium catalyst and hydrogen gas. Indinavir M6 has been extended to synthesize various analogs of indinavir with suitable functional groups. These derivatives are useful in the development of indinavir immunogens, antibodies, and labeled conjugates in the development of indinavir immunoassays.

Disclosed is the development of a protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. The disclosed development relates to a diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein. The protein level is increased or decreased in urine from a patient with IgA nephropathy or TGBM nephropathy compared to urine from a normal patient. According to the disclosed development, the degree of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). As well, the monoclonal antibody is used in early diagnosis and progress detection of IgA nephropathy and development of a novel drug for the purpose of treatment.

The invention relates to nanometer antibodies to human cystatin C and high-sensitivity quantitative-detection kits thereof. The invention reveals nanometer antibodies and monoclonal antibodies to different epitopes of cystatin C, and the antibodies have good compatibility with cystatin C. Through usage of the nanometer antibodies and the monoclonal antibodies, a series of kits capable of conveniently, rapidly and accurately detecting cystatin C can be prepared. The invention provides the nanometer antibodies which can be used for matched detection of cystatin C. With the kits provided by the invention, cystatin C antigens can be sensitively detected, and good repeatability and stable results are obtained; the kits can realize rapid detection and are convenient and fast to use, and the nanometer antibodies need low production cost and are easily available.

The present Invention provides a method for diagnosing and / or prognosing Parkinson's disease dementia (PDD) comprising the step of detecting O-glycosylation. in a protein comprising a Ser / Thr motive, in particular Serpin A1, and / or the level of sialic acid on a protein comprising a Ser / Thr motive, in particular Serpin A1. Further, the present invention relates to a molecule for detecting O-linked glycomoieties in a protein comprising a Ser / Thr motive, in particular Serpin A1, and / or glycosylated i so forms of a Ser / Thr motive comprising protein, in particular Serpin A1, for use in the diagnosis and / or prognosis of Parkinson's disease dementia (PDD), Furthermore, the present invention relates to means for diagnosing and / or prognosing Parkinson's disease dementia (PDD) and a kit for diagnosing and / or prognosing Parkinson's disease dementia (PDD).

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.